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Objectives. Genome wide association studies identified TNFSF member TNF-like protein 1A (TL1A, TNFSF15) as a potential
modulator of ankylosing spondylitis (AS). TL1A is the only confirmed TNFSF ligand of death receptor 3 (DR3, TNFRSF25);
however, its role in disease pathology is not characterised.We evaluated DR3’s role in controlling osteoblast- (OB-) dependent bone
formation in vitro and in vivo.Methods. Osteoprogenitor cells and OB were cultured from male DR3-deficient (DR3ko) and wild-
type (DR3wt) DBA/1 mice. DR3 and RANKL expression were tested by flow cytometry. Alkaline phosphatase and mineralization
were quantified. Osteopontin, osteoprotegerin, and proMMP-9 were measured by ELISA. A fluorescent probe (BoneTag) was used
tomeasure in vivomineralization in 10-month-oldmice. Results. DR3 was expressed on osteoprogenitors andOB fromDR3wt mice.
Alkaline phosphatase, osteopontin, and mineral apposition were significantly elevated in DR3wt cultures. Levels of RANKL were
comparable whilst osteoprotegerin was significantly increased inDR3wt cultures. In vivo incorporation of BoneTag was significantly
lower in the thoracic vertebrae of 10-month-old DR3ko mice. Conclusions. These data identify new roles for DR3 in regulating OB-
dependent bone mineral apposition. They potentially begin to explain the atypical pattern of new bone formation observed in the
axial skeleton of grouped, aging DBA/1 mice.
1. Introduction
In a normal physiological state the process of bone remod-
eling is accomplished through the coupled activities of the
osteoclast (OC) and the osteoblast (OB). The OC is respon-
sible for the degradation of bone while the OB produces the
organic matrix and aids in its mineralization [1, 2]. In certain
pathological conditions, however, OC and OB activity can
become uncoupled leading to an increase or decrease in bone
resorption and bone formation. Increased bone formation
is observed in the spondyloarthritides; delicate marginal
syndesmophytes are common in ankylosing spondylitis (AS)
whilst nonmarginal syndesmophytes are frequently observed
in reactive arthritis and psoriatic arthritis (PsA) [3–5]. The
cause of this excessive focal bone formation byOB is currently
not clear. The immune system and increased expression of
proinflammatory cytokines such as members of the tumour
necrosis factor super family (TNFSF) and their receptors
have been shown to be implicated [3]. Our study assesses
the impact of the TNF receptor superfamily (TNFRSF)
member death receptor 3 (DR3) upon OB-directed mineral
apposition with a view to understanding how it modulates
bone remodelling in the axial skeleton.
Identification of a link between the DR3/TL1A path-
way and the spondyloarthritides was first demonstrated
when single-nucleotide polymorphisms (SNPs) located in the
direct vicinity of theTNFSF15 gene were shown to be strongly
associated with predisposition to spondyloarthropathy [6].
Further evidence for a role of the DR3/TL1A pathway in AS
was provided by Konsta et al., who identified that serum
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levels of TL1A are significantly elevated in AS patients over
healthy controls [7]. The mechanism through which the
DR3/TL1A pathway potentially drives the pathogenesis of the
spondyloarthritides, however, is not clear. Expanded num-
bers of circulating CD8+ CD28− T cells have been identified
in AS patients, which correlated with a more severe course
of disease [8]. A study by Twohig et al., demonstrated that
TL1A signalling on TCR stimulated CD8+ T cells resulted in
increased proliferation [9]. The indirect effect of DR3/TL1A
signalling in CD8+ T cells upon the expansion of OBs or
mineral apposition by OB, however, has not been resolved.
Studies by Bu et al. [10] and Borysenko et al. [11] demon-
strated the expression of DR3 on the surface of a human OB
cell line and primary human OB. These findings imply that
the DR3/TL1A signaling pathway could directly modulate
apposition of bone matrix by OB, a notion that has not been
investigated previously.
This study is the first to specifically investigate the func-
tional role of DR3 onmineral apposition byOB in vitro and in
vivo using male DBA/1 mice lacking the DR3 gene (DR3ko).
The spontaneous development of ankylosing enthesopathy
has been reported previously in aging male DBA/1 mice and
our study provides the first insight toDR3’s role in controlling
new bone formation by OB in the axial skeleton [12]. Here we
report that OB-derived DR3 increases expression of the early
OB differentiation marker alkaline phosphatase, increases
expression of the transcription factors Runx2 and OSX, and
regulates mineral apposition. MMP-9 and OPN production
by OB were measured as surrogate markers of increased OB
activation. OB and OC cross talk is an important factor in
bone homeostasis. We measured OB-derived RANKL and
OPG production to determine the role of DR3 in regulating
OC differentiation byOB.These findings examine potentially
important, hitherto unknown, mechanisms whereby DR3
regulates OB-dependent bone homeostasis.
2. Materials and Methods
2.1. Animals. All experiments were undertaken in male
DBA/1 DR3wt andDR3ko mice generated in a DR3het×DR3het
colony. The DBA/1 DR3ko strain was generated through
backcrossing C57BL/6 DR3het mice [13] with DBA/1 wild-
type mice for 7 generations. All DBA/1 DR3wt and DR3ko
animals were generated in-house. Animals used for in vitro
experiments were 8–12 weeks of age. Animals for the in vivo
BoneTag experiments were 10 months of age. Animals were
housed in filter top cages at a constant temperature and
humidity on a 12-hour light/dark cycle. Food and water were
available ad libitum. All procedures were approved by the
Local Research Ethics Committee and performed in strict
accordance with Home Office approved license PPL 30/2361.
2.2. OPC and OB Cell Culture. To obtain osteoprogenitors
(OPCs) bone marrow was isolated from the femora of DR3wt
(𝑛 = 5) and DR3ko (𝑛 = 5) DBA/1 mice and cultured in
𝛼MEM supplemented with 20% foetal calf serum, 50𝜇g/mL
Penicillin-Streptomycin (control medium) and 5% CO
2
at
37∘C. At confluence OPCs were detached from the culture
vessel by scraping and were replated in a 12-well plate at a
density of 4 × 104 cells/well in control medium. Osteoblasts
were subsequently differentiated from OPCs by addition of
𝛼MEM supplemented with 10% foetal calf serum, 50𝜇g/mL
Penicillin-Streptomycin, 10mM 𝛽-glycerophosphate, 50 𝜇g/
mL ascorbic acid, and 10 nM dexamethasone (mineralisation
medium). Osteoblasts were maintained for up to 26 days (5%
CO
2
at 37∘C) with medium changes every 3-4 days.
2.3. Cellular Staining and Flow Cytometry. OPCs (DR3wt 𝑛 =
6, DR3ko 𝑛 = 4) and OB (DR3wt 𝑛 = 3, DR3ko 𝑛 = 2) were
cultured for 15 days using the method described above. Cells
were removed from the culture vessel and incubated with
Fc block (BD Pharmingen, CA, USA) for 15min followed
by a 30min block with 2% normal goat serum. Cells were
stained with either polyclonal 𝛼-mouse DR3-biotin (BAF
2437; R&D Systems, MN, USA) followed by SA-APC (Molec-
ular Probes, OR, USA) or PE-conjugated 𝛼-mouse RANKL
mAb (IK22/5; Santa Cruz Biotechnology Inc., TX, USA).
Data were acquired on a BD Accuri C6 flow cytometer and
analysed with CFlow software (BD Biosciences).
2.4. TL1A RT-PCR. RNA was extracted from OPCs and
mineralising OB (DR3wt 𝑛 = 1, DR3ko 𝑛 = 1) using RNeasy
(QIAGEN) following manufacturer’s instructions and con-
verted to cDNA using SuperScript II Reverse Transcriptase
(Life Technologies). RT-PCR was performed according to
standard Life Technologies protocols. PCR primers were as
follows: TL1A, forward 5󸀠-CAG CAG AAG GAT GGC AGA-
3󸀠 and reverse 5󸀠-CTCTGGCCTGTGTCTACA-3󸀠, giving a
91-bp product; and 𝛽-actin, forward 5󸀠-CGGCCAGGTCAT
CAC TAT TG-3󸀠 and reverse 5󸀠-CTC AGT AAC CCG CCT
AG-3󸀠, giving a 450-bp product.ThePCR comprised 33 cycles
with an annealing temperature of 59∘C. The PCR products
were size fractionated by agarose gel electrophoresis and
analysed using aUVPBioDoc It imaging system (Cambridge,
UK).
2.5. Quantitative PCR. RNA was extracted from OPCs and
OB and converted to cDNA as described above (DR3wt 𝑛 =
1, DR3ko 𝑛 = 1). Quantitative PCR was performed using
the iCycler iQ system (Bio-Rad) with RT2 Real Time SYBR
green PCR master mix (SA Biosciences) following the rec-
ommended protocol for SYBR green (Bio-Rad). Assays were
run in duplicate. mRNA levels were determined using the
comparative Ct method and normalized to 𝛽-actin mRNA
levels. Primers used for quantitative PCR were as fol-
lows: RUNX2, forward 5󸀠-CCCTGAACTCTGCACCAAGT-
3󸀠 and reverse 5󸀠-TGGCTCAGATAGGAGGGGTA-3󸀠; OSX,
forward 5󸀠-TCTCCATCTGCCTGACTCCT-3󸀠 and reverse
5󸀠-CAGGGGACTGGAGCCATAGT-3󸀠;𝛽-actin as above.
2.6. Alkaline Phosphatase and Mineralisation Staining. Alka-
line phosphatase (ALP) activity was determined in OB
cultures (DR3wt 𝑛 = 5, DR3ko 𝑛 = 5) using SigmaFast BCIP/
NBT stain (Sigma). The mineralized matrix was stained for
calcium deposition by Alizarin-red staining. Briefly, at time
points indicated in results, cultures were fixed with a 4%
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formaldehyde/PBS solution for 15min. Cultures were then
incubated with either SigmaFast BCIP/NBT solution or
Alizarin-red (1% solution in water) for 30 minutes. Cul-
tures stained for mineral apposition were washed with 50%
methanol to remove nonspecific background. Plates were air-
dried and scanned and the percentage of the well was covered
by ALP positive cells or mineral calculated with Image J
(NIH).
2.7. Measurement of Soluble Mediators in Cell Culture Super-
natant. Expression of solublemediators in cell culture super-
natants was analysed by ELISA using mouse osteoprotegerin
(OPG), pro MMP-9, receptor activator of nuclear factor
kappa-B ligand (RANKL) and osteopontin (OPN) DuoSet
kits (all R&D Systems).
2.8. In Vivo Imaging. DBA/1 male mice were housed together
as previously described [12]. Animals at 10 months (DR3wt
𝑛 = 3, DR3ko 𝑛 = 3) of age were subjected to either an
intraperitoneal injection with IRDye 680 BoneTag optical
probe (0.08 nmol/g) or equal volume of PBS as control.
After 24 hours animals were sacrificed by CO
2
asphyxiation.
Images were taken using the Xenogen IVIS 200 (excitation
wavelength 676 nm, emission wavelength 698 nm, f-stop 1)
and rectangular regions of interest of fixed dimensions were
selected at the thoracic spine, knee, and tail. Total efficiency
of the marker was analyzed using the Live Image software,
version 2.50.2 (Caliper). The efficiency values obtained from
the PBS control animals were subtracted from the values
obtained with BoneTag, to account for background autofluo-
rescence.
2.9. Statistical Analysis. Data are expressed as mean ± SEM
and statistical analysis performed using the Mann-Whitney
𝑈 test for nonparametric data, unpaired 𝑡-test for parametric
data, or 2-way analysis of variance (ANOVA) usingGraphPad
Prism software (GraphPad, San Diego, CA, USA). 𝑃 values of
≤0.05 were considered significant and values of ≤0.01 were
considered highly significant.
3. Results
3.1. Expression of DR3 andTL1A byOPCs andOB. Expression
of DR3 on the human MG63 osteosarcoma cell line has
previously been demonstrated by Borysenko et al. [11]. Here
we investigated DR3 expression on primary, murine OPCs
and OB using flow cytometry. The signal from the surface
of DR3wt OPCs was 1.8 ± 0.2-fold higher than the isotype
control (Figure 1(a)) and was significantly higher than from
DR3ko OPCs (𝑃 ≤ 0.05). Levels of DR3 signal were reduced
onDR3wt mineralising OB (1.4±0.8-fold increase) compared
to the OPCs. RT-PCR analysis of DR3wt- and DR3ko-derived
OPCs andOB showed constitutive expression ofTL1AmRNA
across a 15 day time course (Figure 1(b)).
3.2. DR3/TL1A Signalling Promotes RUNX2 and OSX Expres-
sion. To identify whether DR3 signalling in OPCs and
OB modulates Runx2 and OSX expression qPCR was per-
formed on differentiating OB across a 14-day time course
(Figure 1(c)). No difference in RUNX2 and OSX levels was
detected between the DR3wt andDR3ko cultures after the first
3 days of differentiation. At day 7 an increase in Runx2 gene
expressionwas observed in theDR3wt cultures. At day 14 both
Runx2 and OSX expression levels were elevated in the DR3wt
cultures compared to the DR3ko cultures.
3.3. Effect of DR3 on OB Differentiation, OPN and Pro MMP-
9 Expression and Mineral Apposition. To assess the effect of
DR3 on OB differentiation and mineral apposition, miner-
alization assays were performed and expression of the early
OB differentiation marker ALP was studied. At the earliest
time point assessed (day 17), the percentage area of the wells
demonstrating ALP-positive cells was elevated in the DR3wt
(41 ± 5%) versus DR3ko (30 ± 5%) cultures. These levels
did not vary significantly across the 26-day time course,
translating into significantly increased levels of ALP staining
in DR3wt cultures (𝑃 ≤ 0.05; Figure 2(a)).
To see whether the increase in DR3wt ALP expression was
accompanied by an increase in OB activation markers, levels
of the Ca2+ binding osteoid protein (OPN) and a regulator
of bone matrix maturation (pro MMP-9) were measured in
culture supernatants [14, 15]. Levels of OPNwere significantly
elevated in DR3wt cultures compared to DR3ko cultures over
the 26-day time course (𝑃 < 0.01; Figure 2(b)). Levels ofOPN
peaked at day 17 in the DR3wt (252± 55 ng/mL) and at day 23
in the DR3ko cultures (178 ± 70 ng/mL). Levels of pro MMP-
9 were initially higher at day 3 in the DR3wt cultures versus
DR3ko (3.4 ± 0.5 ng/mL versus 1.5 ± 0.2 ng/mL; 𝑃 < 0.01).
DR3wt pro MMP-9 levels peaked at day 7 (4.1 ± 1.7 ng/mL)
and decreased over the duration of the time course to 0.7 ±
0.3 ng/mL. In contrast, expression of pro MMP-9 in the
DR3ko cultures increased over the culture period and peaked
at day 20 (3.8 ± 1.7 ng/mL; Figure 2(c)).
To identify whether the increase in DR3wt OB differ-
entiation and OPN expression correlated with an effect on
mineral apposition, levels of mineralization in the cultures
were evaluated. At day 17 comparable levels of mineralization
were observed between theDR3wt (4±1%) andDR3ko (3±1%)
cultures.Mineral appositionwas significantly increased in the
DR3wt cultures at day 23 (14±2%;𝑃 < 0.001) and day 26 (14±
2%;𝑃 < 0.001) when compared toDR3ko cultures (5±1%and
5 ± 1%, resp.). This resulted in significantly increased levels
of mineral apposition across the time course in the DR3wt
cultures (𝑃 < 0.001; Figure 2(d)). Having demonstrated that
DR3 affects OB differentiation and mineral apposition, in
vitro, we investigated whether it could have a potential effect
on OB control of osteoclast formation.
3.4. Effect of DR3 onOB-Derived RANKL andOPG. To inves-
tigate whether DR3 had a role in regulating OB control of
OC formation, levels of OB-derived RANKL and OPG were
studied. OPC and OB cell surface RANKL expression were
comparable between DR3wt and DR3ko cells (Figure 3(a)).
No soluble RANKL was detected in any culture supernatants
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Figure 1: Expression of DR3 by murine OPCs and OBs. (a) DR3wt (𝑛 = 6) and DR3ko (𝑛 = 4) OPCs and OB (DR3wt 𝑛 = 3, DR3ko 𝑛 = 2)
were analysed for DR3 signal by flow cytometry. DR3 signal was observed on DR3wt OPCs and OBs. A small subpopulation of DR3wt OPCs
displayed higher levels of DR3 signal (shaded area = isotype control, black outline = DR3 antibody). (b) RNA was extracted from DR3wt and
DR3ko OPCs and OB and tested for TL1A mRNA by RT-PCR. A 91 bp band corresponding to TL1A mRNA was detected at all time-points
demonstrating constitutive expression of TL1A mRNA by DR3wt and DR3ko OPCs and OB. (c) Samples (DR3wt 𝑛 = 1, DR3ko 𝑛 = 1) were
tested by qPCR at time points indicated to determine whether DR3 signalling modulates (i) Runx2 or (ii) OSX gene expression. Increased
expression of Runx2 was detected at day 7 and day 14 while increased OSX expression was only detected at day 14 in the DR3wt compared to
the DR3ko.
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Figure 2: Expression of ALP, OPN, pro MMP-9, and mineral apposition in DR3wt and DR3ko osteoblast cultures. (a) DR3wt (𝑛 = 5) and
DR3ko (𝑛 = 5) derived OB were cultured and the percentage of well area covered by ALP+ cells was calculated. ALP staining was significantly
higher in the DR3wt compared to the DR3ko cultures across the 26-day time course (𝑃 ≤ 0.01). Supernatants from OB cultures were tested
for soluble levels of (b) OPN and (c) pro MMP-9. Across the time course significantly increased levels of OPN were detected in DR3wt versus
DR3ko cultures (𝑃 ≤ 0.01). (d) Levels of mineral apposition in the cultures were tested by alizarin-red staining. Significantly increased levels
of mineralization were observed in the DR3wt cultures at days 23 and 26 (𝑃 ≤ 0.001) compared to the DR3ko.This translated into a significant
increase in the level of mineral apposition across the 26-day time course (𝑃 ≤ 0.001).
(data not shown). In contrast, significantly increased levels of
OPG were detected across the 26-day time course in DR3wt
compared to DR3ko cultures (𝑃 < 0.01; Figure 3(b)). Levels
of OPG peaked at day 14 (62 ± 37 ng/mL) in DR3wt cultures,
while in DR3ko cultures OPG levels reached a peak of 19 ±
7 ng/mL on day 17.
3.5. Assessing the Impact of DR3 on Bone Formation In Vivo.
In vitro DR3 has been shown to regulate OB differentiation
and mineral apposition while promoting expression of the
antiosteoclastogenic cytokine OPG. To identify what effect
this would have on in vivo bone formation male DBA/1
mice were aged for 10 months as a spontaneous model of
ankylosing enthesopathy [12]. Bone formation over a 24-hour
period was measured at three sites (knee, tail, and thoracic
vertebra) via the incorporation of the fluorescent probe Bone-
Tag. Significantly increased fluorescence efficiency values
were observed in the DR3wt thoracic spine (2.94 ± 0.20 ×
10
−5; 𝑃 < 0.05) compared to the DR3ko thoracic spine
(1.76 ± 0.26 × 10−5; Figure 4(c)), suggesting DR3ko mice
exhibit some resistance to the long-term development of
spontaneous ankylosing enthesopathy observed in DBA/1
strain wild-type animals.
4. Discussion
Spondyloarthritides such as AS and PsA are characterized
by the formation of syndesmophytes [3–5]. Mechanisms
that control this increased aberrant bone apposition are not
clear. This study provides the first direct evidence of DR3’s
involvement in OB-dependent new bone formation in vitro
and in vivo.We demonstrate (usingDR3ko mice) thatDR3has
an important role in the differentiation of OB and subsequent
mineralization of the organic matrix by OB. We also reveal
6 Journal of Immunology Research
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Figure 3: Effect of DR3 on OB-derived RANKL and OPG. (a) Cell surface expression of RANKLwas analyzed on DR3wt- and DR3ko-derived
OPCs and OB by flow cytometry. Both DR3wt and DR3ko OPCs displayed a 3-fold increase in RANKL signal over isotype control. RANKL
signal increased to 5-fold over isotype in DR3wt and DR3ko OB. (b) Levels of soluble OPG were measured in culture supernatants by ELISA
(DR3wt 𝑛 = 5, DR3ko 𝑛 = 5). Expression of OPG was significantly elevated in the DR3wt compared to DR3ko OB cultures over the 26-day
time course (𝑃 ≤ 0.01).
a novel pathway whereby DR3 increases OPG production
by OB thereby potentially decreasing OC differentiation. In
vivo, we show that gene deletion of DR3 protects the axial
skeleton against excessive bone formation, a bone phenotype
previously observed in aging DBA/1 male mice [12].
In the current study we reveal that DR3 is expressed
on the cell surface of primary murine OPCs and OBs. DR3
expression on mouse OPC was shown to be comparable to
that reported on the human OB MG63 cell line [11]. Cell
surface expression of DR3 was reduced on mineralizing OB
suggesting that DR3 may be temporally regulated during
OB differentiation. In addition to DR3, the current study
identified for the first the time expression of TL1A mRNA
by primary OPCs and OB. These data suggest a potential
autocrine role for the DR3/TL1A pathway in modulating OB
differentiation and mineral apposition.
The notion that DR3 signalling has a role in OB differ-
entiation was supported by the mineralization assay results.
Levels of ALP expression and mineral apposition were
significantly increased in the DR3wt cultures. This could be
explained by DR3 signalling increasing either OB differen-
tiation or proliferation, as has been described for effector T
cells [16–18]. Total OB cell numbers at experiment end-point
were, however, comparable between the DR3wt and DR3ko
cultures (data not shown), suggesting that the increase inALP
expressing cells was due to DR3 promoting differentiation.
This result is at odds with data described by Borysenko et al.
[11], who demonstrated that cross-linking of DR3 with an
antibody on MG63 cells induced apoptosis and inhibited
differentiation. However, Borysenko and colleagues were
unable to reproduce their results with TL1A or in primary
human OB, suggesting that activation following receptor
cross-linking may differ from actions of the natural ligand.
Further support for DR3 having a role in the regulation of OB
differentiation is provided by the analysis of Runx2 and OSX
gene expression. Runx2 and OSX are critical transcription
factors involved in OB differentiation, the absence of which
results in the maturational arrest of the OB [19–21]. In the
present study both Runx2 and OSX were elevated in the
DR3wt, but notDR3ko, cultures at later time points.These data
suggest a possible mechanism through which OB-dependent
DR3 signalling potentially modulates OB differentiation.
The DR3-dependent increase in OB differentiation in
the DR3wt was associated with increasing mineral apposi-
tion in the cultures. This elevation in mineral apposition
corresponded with a significant increase in OPN expression
in the DR3wt cultures. OPN is suggested to play a role in
osteogenesis by attachment of the OB to the organic matrix
and to regulate crystal size during mineralization [14, 22].
Interestingly OPN is in part transcriptionally regulated by
Runx2 [22, 23] suggesting that in OBs, DR3 modulates OPN
expression indirectly via this transcription factor. Before the
OB can commence with the formation of newly mineralized
bone the organic matrix must first undergo a maturation
process. In a study by Filanti et al. [15] members of the matrix
metalloproteinase (MMP) family, includingMMP-2, -9, and -
14, were increased inOB cultures at the time of nodule forma-
tion suggesting that they play a significant role in this matrix
maturation process. Previous studies have demonstrated that
DR3 signalling has a role in MMP-9 production; the THP-1
cell line has been shown to increase MMP-9 expression fol-
lowing treatment with TL1A [24, 25]. In addition, a study by
Wang et al. [26] described significantly lower levels of MMP-
9 in the joints of DR3ko mice with antigen induced arthritis
compared to their DR3wt counterparts during the early stages
of disease. In the present study we sought to determine
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Figure 4: Incorporation of BoneTag into the knee, tail, and thoracic spine of 10-month-old DR3wt and DR3ko mice (DR3wt 𝑛 = 3, DR3ko 𝑛 =
3). Mice were injected with the fluorescent probe BoneTag and in vivo bone formation was analyzed. No differences in bone formation were
observed in the (a) knee or (b) tail. A significant increase in bone formation was observed in the (c) thoracic spine of DR3wt compared to
DR3ko mice (𝑃 ≤ 0.05). Area quantified illustrated by red circle/box.
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whether OB-dependent DR3 signalling affected osteoblastic
MMP-9 expression, which would potentially modulate OB
mineral apposition. A difference in the MMP-9 expression
pattern was observed between the DR3wt andDR3ko cultures;
with higher levels of pro MMP-9 observed at the early time
points in the DR3wt cultures. This early expression of MMP-
9 shows similarity to the phenotype described by Wang et al.
[26] and taken together the results suggest thatDR3 signalling
has a central role in controlling levels ofMMP-9.Unpublished
work from our laboratory also suggests that the DR3 pathway
may have a key role in the activation of MMP-9 from the pro
form.
In addition to anOB specific effect, we have shown in vitro
that OB DR3-dependent signalling results in significantly
elevated expression of the soluble RANKL inhibitor OPG.
This data suggests that OBDR3 signalling has the potential to
in-directlymodulate OC formation; where the increasedOB-
derived OPG inhibits OC formation and subsequently bone
resorption [27]. This is in contrast to the direct contribution
of DR3 signalling on osteoclastogenesis during inflammatory
arthritis where DR3 has been revealed to enhance OC
formation [28]. Interestingly, significantly increased levels of
OPG have been detected in the serum from AS patients and
are linked to poor physical mobility [29].
To investigate whether DR3 regulation of OB differ-
entiation and mineral apposition could contribute towards
the increased bone formation associated with the spondy-
loarthritides, we examined the effect of DR3 on in vivo
bone formation in the spontaneous ankylosing enthesopa-
thy model [12]. The results from the 10-month-old mice
are consistent with the hypothesis that OB-dependent DR3
signalling has a significant role in regulating the atypical
bone formation observed in the axial skeleton of mice with
spontaneous ankylosing enthesopathy. The increased bone
formation observed in the thoracic spine of DBA/1 DR3wt
mice is analogous to the pattern of marginal/nonmarginal
syndesmophyte formation observed in the spine of PsA and
AS patients [30, 31]; thus this observation could have impor-
tant implications in the understanding of the pathogenesis of
these diseases.
The results from the present study provide the first
evidence for a functional role for DR3 signalling in new bone
formation. We have shown that cell surface DR3 is tem-
porally expressed by OPCs and OB while TL1A mRNA is
constitutively expressed and that an autocrine signalling loop
may promote Runx2 and OSX expression, consequently
modulating OB differentiation and mineral apposition. OB-
dependent DR3 signalling increased levels of the soluble
inhibitor OPG and could, therefore, indirectly regulate OC
formation and bone resorption. Finally, in vivo, the absence of
DR3 leads to differences in bone formation compared towild-
type DBA/1 mice, which in 10-month-old animals suggest
resistance to the development of spontaneous ankylosing
enthesopathy that has been previously described in this
strain [12]. These data, taken with the study by Konsta et al.
[7], suggest that OB-dependent DR3 signalling could be an
important contributory factor in the atypical bone pathology
associated with diseases such as PsA and AS.
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